Sage Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sage Therapeutics generated cash of -$540,585,000, which is less than the previous year. Cash used in financing activities reached the amount of $6,027,000 last year. Net change in cash is therefore -$91,645,000.
Cash Flow
| 2014 | -27.04M | -128K | 146.87M |
|---|---|---|---|
| 2015 | -70.68M | -198K | 129.86M |
| 2016 | -118.67M | -230.54M | 330.98M |
| 2017 | -219.27M | 15.17M | 341.81M |
| 2018 | -260.67M | -512.46M | 659.35M |
| 2019 | -528.70M | -143.15M | 607.62M |
| 2020 | 664.28M | 442.68M | 426.76M |
| 2021 | -378.18M | -1.00B | 13.33M |
| 2022 | -460.03M | 325.43M | 3.07M |
| 2023 | -540.58M | 442.91M | 6.02M |
SAGE Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 163.96M | 295.50M | 1.66B | 129.07M | 193.31M | 307.08M | 168.51M | 186.75M | 127.76M | 8.06M |
Operating activities | ||||||||||
Net income | -541.48M | -532.78M | -457.89M | 606.07M | -680.23M | -372.88M | -270.12M | -158.98M | -94.49M | -33.81M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.39M | 1.12M | 4.18M | 2.63M | 2.28M | 1.14M | 531K | 281K | 115K | 51K |
Stock-based compensation expense | 73.36M | 61.60M | 104.62M | 95.99M | 153.23M | 0 | 35.53M | 23.02M | 15.24M | 2.51M |
| Deferred income tax benefit | 73.36M | 61.60M | 104.62M | 95.99M | 153.23M | 0 | 35.53M | 23.02M | 15.24M | 2.51M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 4.84M | -18.50M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | -4.84M | 18.50M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -8.49M | 8.43M | 6.68M | -11.51M | -18.78M | 24.54M | -3.69M | 7.79M | 2.69M | 441K |
Cash generated by operating activities | -540.58M | -460.03M | -378.18M | 664.28M | -528.70M | -260.67M | -219.27M | -118.67M | -70.68M | -27.04M |
Investing activities | ||||||||||
Purchases Of Investments | -594.67M | -881.03M | -1.99B | -458.72M | -1.30B | -1.48B | -244.40M | -259.09M | 0 | 0 |
Investments In Property Plant And Equipment | -553K | -937K | -372K | -345K | -5.75M | -2.86M | -1.36M | -1.42M | -198K | -128K |
Acquisitions Net | 0 | -326.37M | 1.00B | -443.02M | 137.40M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 442.91M | 325.43M | -1.00B | 442.68M | -143.15M | -512.46M | 15.17M | -230.54M | -198K | -128K |
Financing activities | ||||||||||
Common Stock Issued | 6.93M | 3.11M | 14.71M | 417.5M | 561.27M | 631.49M | 326.02M | 330.17M | 129.72M | 96.29M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -903K | -43K | -1.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -5.73M | -6.78M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 6.02M | 3.07M | 13.33M | 426.76M | 607.62M | 659.35M | 341.81M | 330.98M | 129.86M | 146.87M |
Net Change In Cash | -91.64M | -131.53M | -1.36B | 1.53B | -64.23M | -113.77M | 137.71M | -18.23M | 58.98M | 119.7M |
Cash at end of period | 72.32M | 163.96M | 295.50M | 1.66B | 129.07M | 193.31M | 306.23M | 168.51M | 186.75M | 127.76M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |